Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07140055
PHASE1

A Research Study to Evaluate BLX-7006 in Healthy Adults

Sponsor: Biolexis Therapeutics

View on ClinicalTrials.gov

Summary

This study will test an oral medicine called BLX-7006, which acts like the hormone Glucagon-like Peptide-1 (GLP-1) to help control blood sugar and body weight. Current GLP-1 medicines are given by injection. This study will see if BLX-7006 is safe, how the body processes it, and whether food changes how it is absorbed. The main goal is to see if BLX-7006 is safe and well tolerated. Secondary objectives of the study will measure how BLX-7006 moves through the body after an oral dose, including how quickly it is absorbed, how long it stays in the blood, and how the body removes it. It will also look at how the drug affects the body by looking at markers of glucose metabolism.

Official title: A Phase 1 Randomized, Double-blind, Placebo-controlled Single-ascending Dose and Multiple-ascending Dose (SAD and MAD) Trial to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Novel Glucagon-like Peptide-1 Receptor Agonist (GLP-1RA) BLX-7006 in Healthy Adults With a Body Mass Index (BMI) of 20 - 35 kg/m2

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

76

Start Date

2025-09

Completion Date

2026-05

Last Updated

2025-08-24

Healthy Volunteers

Yes

Interventions

DRUG

BLX-7006

BLX-7006 Single or Multiple doses administered orally as a tablet

DRUG

Placebo

Participants will receive matching placebo of BLX-7006 for each of the oral cohorts.

Locations (1)

Nucleus Network Brisbane Clinic

Brisbane, Queensland, Australia